Navigation Links
TPI Receives GMP Certification for JCM Facility
Date:1/19/2012

CHENGDU, China, Jan. 18, 2012 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI, or the "Company"), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced the Company has received the Good Manufacturing Practice (GMP) certification for its 250-ton Jiangchuan Macrolide Facility (JCM) designated as "CHUAN M0799" valid through the period of December 31, 2011 until December 31, 2015.

Detailed information of the GMP certification for JCM facility can also be found in the official site of Sichuan Food and Drug Administration (www.scfda.gov.cn/ (Chinese version)).

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about TPI, please visit: http://www.tianyinpharma.com

About GMP

Good manufacturing practice (GMP) are a set of comprehensive quality management system required for pharmaceutical manufacturing covering the manufacture and testing of pharmaceuticals including APIs, diagnostics, foods, pharmaceutical products, and medical devices. GMPs are guidelines that outline the aspects of production that ensure the quality of a product.

GMP certification is conducted based on several underlying basic principles: 1) Clearly defined manufacturing processes that are controlled with critical processes validated to ensure consistency and compliance with specifications during the production; 2) Good Documentation Practices; 3) Operators are trained to carry out and document procedures; 4) Records are made, manually or by instruments, during manufacture that demonstrate that all the steps required by the defined procedures and instructions were carried out and that ensure the quantity and quality of the drug; 5) Records of manufacture and distribution that trace the complete history of a batch are retained in a comprehensible and accessible form. 6) The distribution of the drugs minimizes any risk to their quality; 7) A system is available for recalling any batch of drug from sale; 8) Complaints about marketed drugs are examined, the causes of quality defects are investigated, and appropriate measures are taken with respect to the defective drugs and to prevent recurrence.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com, or email ir@tpi.asia
Tel: +86-28-8551-6696 (Chengdu, China)
     +86-134-3655-0011 (China)

Address:
Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China


'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
2. Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples
3. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
4. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
5. BioNeutral Group Receives $400,000 in Equity Financing
6. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
7. Intimate Bridge 2 Conception, Inc. Receives $4.3M
8. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
9. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
10. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
11. Watsons Generic Yaz(R) Receives FDA Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... , ... There’s a winning streak at Voxx Analytics: the tech company has ... the award last year as well. Employees nominate their companies for the honor, and ... to the tech company’s upbeat environment as a reason. “We don’t answer to Wall ...
(Date:12/9/2016)... ALBANY, New York , December 9, 2016 /PRNewswire/ ... Research states that the top five players in the  ... of 62.7% in the overall market in 2015. Players ... and Perkin Elmer have remained dominant in the global ... persistent efforts to ensure product innovation. Product upgrades and ...
(Date:12/9/2016)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") ... announce that Biohaven has issued today the following press ... (PRWEB) Dec 9, 2016 - Biohaven Pharmaceutical Holding ... the U.S. Food and Drug Administration ("FDA") has granted ... candidate BHV-0223, an orally dissolving tablet being developed for ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 This report ... following Product Segments: Acid Based (Humic, Amino, & Fulvic), Extract ... by the following Crop Types: Ornamental & Turf, Row Crops, ... US, Canada , Japan ... , Latin America , and Rest of ...
Breaking Biology Technology:
(Date:11/17/2016)... INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it has just ... servers in organizations that require high-performance scale-out plus high speed data transfer storage solutions. ... ... ... Setting up a ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:11/14/2016)... 2016  xG Technology, Inc. ("xG" or the "Company") ... communications for use in challenging operating environments, announced its ... Management will hold a conference call to discuss these ... Time (details below). Key Recent Accomplishments ... binding agreement to acquire Vislink Communication Systems. The purchase ...
Breaking Biology News(10 mins):